65,437 trials
Adenocarcinoma of the Prostate · Recurrent Prostate Cancer · Stage I Prostate Cancer
Primary: Proporation of Subjects Achieving Partial Response, Stable Disease or Progressive Disease Based on PSA Response Rates — 9; 2; 1 Participants
Infections, Meningococcal
Primary: Vaccine Response to Meningococcal Antigens for Serum Bactericidal Assay Using Rabbit Complement (rSBA) — 82.7; 69.7; 94.4; 90.3 Percentage of subjects
Nonalcoholic Steatohepatitis
Primary: The Effect of Obeticholic Acid on Low-density Lipoprotein (LDL) Concentration (Least Squares Mean Change From Baseline at Week 16) — -33.2; -44.27; -39.54; -53.33 mg/dL
Ovarian Carcinoma · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Phase 1: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel — 40 mg
Pain, Postoperative
Primary: Average Inpatient Postoperative Pain Score — 2.7; 2.4 units on a scale
Adenocarcinoma of the Prostate · Bone Metastases · Soft Tissue Metastases
Primary: Number of Participants With Increase in SUV Uptake — 0; 0 Participants
Parkinson's Disease · Sleep Disordered Breathing
Primary: Tests to Determine the Apnea-hypopnea Index (Number of Apneas and Hypopneas Per Hour of Sleep) — 5.2; 20 apnea hypopnea index
Cannabis Dependence · Marijuana Dependence
Primary: Change From Baseline in Cannabis Use at 10 Weeks — 268.8; 286.7; 490.3; 216.9 Ratio
Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)] — 31.0; 20.0 percentage of participants
Type 2 Diabetes
Primary: Mean Change in HbA1c — -1.41; -1.07 percentage (%) — p=0.0008
Improve the Informed Consent Process
Primary: Quality of Informed Consent Part A (QuIC-A) Score — 81.8; 80.5 units on a scale — p=0.37
Conditions Requiring Sinonasal Surgery
Primary: Number of Participants With Presence or Absence of Blood/Secretions in Trachea and Larynx Based on Soiling Score — 12; 10; 15; 21 Participants
Burns
Primary: Primary Endpoint: Reduction in CRP Level Over Time, Compared to Placebo Measured at Baseline and Days 3, 7, 14. The Mean CRP Levels at Specified Days Will be the…
Hemophagocytic Lymphohistiocytosis · Chronic Active Epstein-Barr Virus Infection · Chronic Granulomatous Disease
Primary: Percentage of Participants With Overall Survival (OS) — 80.4; 66.7 percentage of participants
Postoperative Dental Pain
Primary: Total Pain Relief From 0 to 6 Hours (TOTPAR[6]) — 6.94; 6.21; 7.00; 14.43 units on a scale